TR201905233T4 - Dirençli bakteriyel enfeksiyonların tedavisine yönelik kombinasyon tedavisi. - Google Patents

Dirençli bakteriyel enfeksiyonların tedavisine yönelik kombinasyon tedavisi. Download PDF

Info

Publication number
TR201905233T4
TR201905233T4 TR2019/05233T TR201905233T TR201905233T4 TR 201905233 T4 TR201905233 T4 TR 201905233T4 TR 2019/05233 T TR2019/05233 T TR 2019/05233T TR 201905233 T TR201905233 T TR 201905233T TR 201905233 T4 TR201905233 T4 TR 201905233T4
Authority
TR
Turkey
Prior art keywords
pharmaceutically acceptable
acceptable salt
sulbactam
compound
imipenem
Prior art date
Application number
TR2019/05233T
Other languages
English (en)
Turkish (tr)
Inventor
Lodewijk Maria DEJONGE Boudewijn
Francois DURAND-REVILLE Thomas
Cunera Verheijen Jeroen
Tommasi Ruben
Mueller John
Original Assignee
Entasis Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entasis Therapeutics Ltd filed Critical Entasis Therapeutics Ltd
Publication of TR201905233T4 publication Critical patent/TR201905233T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TR2019/05233T 2014-11-17 2015-11-17 Dirençli bakteriyel enfeksiyonların tedavisine yönelik kombinasyon tedavisi. TR201905233T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462080667P 2014-11-17 2014-11-17

Publications (1)

Publication Number Publication Date
TR201905233T4 true TR201905233T4 (tr) 2019-05-21

Family

ID=54704148

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/05233T TR201905233T4 (tr) 2014-11-17 2015-11-17 Dirençli bakteriyel enfeksiyonların tedavisine yönelik kombinasyon tedavisi.

Country Status (31)

Country Link
US (2) US9968593B2 (enExample)
EP (1) EP3221313B1 (enExample)
JP (1) JP6764862B2 (enExample)
KR (1) KR102542392B1 (enExample)
CN (1) CN107108624B (enExample)
AU (1) AU2015350128B2 (enExample)
BR (1) BR112017010132B1 (enExample)
CA (1) CA2966632C (enExample)
CY (1) CY1121384T1 (enExample)
DK (1) DK3221313T3 (enExample)
EA (1) EA033829B1 (enExample)
ES (1) ES2717776T3 (enExample)
HK (1) HK1244798B (enExample)
HR (1) HRP20190580T1 (enExample)
HU (1) HUE044061T2 (enExample)
IL (1) IL251979B (enExample)
LT (1) LT3221313T (enExample)
ME (1) ME03357B (enExample)
MX (1) MX2017006383A (enExample)
MY (1) MY196240A (enExample)
PH (1) PH12017500852B1 (enExample)
PL (1) PL3221313T3 (enExample)
PT (1) PT3221313T (enExample)
RS (1) RS58429B1 (enExample)
SG (1) SG11201703633TA (enExample)
SI (1) SI3221313T1 (enExample)
SM (1) SMT201900187T1 (enExample)
TR (1) TR201905233T4 (enExample)
TW (1) TWI690317B (enExample)
WO (1) WO2016081452A1 (enExample)
ZA (1) ZA201703245B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE044061T2 (hu) 2014-11-17 2019-09-30 Entasis Therapeutics Ltd Kombinációs terápia rezisztens bakteriális fertõzések kezelésére
WO2017203266A1 (en) * 2016-05-25 2017-11-30 Entasis Therapeutics Limited Combination therapy for treatment of resistant bacterial infections
IL289686B2 (en) * 2016-09-16 2023-03-01 Entasis Therapeutics Ltd Beta-lactamase inhibitor compounds
EP3301094A1 (en) * 2016-09-30 2018-04-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
EA037916B1 (ru) * 2017-02-08 2021-06-07 Энтасис Терапеутикс Лимитед Соединения-ингибиторы бета-лактамаз
LT3630111T (lt) 2017-05-08 2022-03-10 Entasis Therapeutics, Inc. Junginiai ir būdai, skirti bakterinių infekcijų gydymui
CN109422765B (zh) * 2017-09-05 2020-08-28 香港理工大学深圳研究院 C类β-内酰胺酶抑制剂及其制备方法和应用
ES2953362T3 (es) * 2018-03-13 2023-11-10 Sepsia Therapeutics S L Péptidos de unión bacteriana para el tratamiento de enfermedades infecciosas y procesos inflamatorios relacionados
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
DK3833665T3 (da) 2018-08-09 2023-10-09 Antabio Sas Diazabicyclooctanoner som hæmmere af serin-beta-lactamaser
CN111658642A (zh) * 2019-03-05 2020-09-15 广州新创忆药物临床研究有限公司 一种治疗耐碳青霉烯类抗生素鲍曼不动杆菌感染的组合物
TWI715397B (zh) * 2019-12-31 2021-01-01 高雄榮民總醫院 根據領先標準將同儕數據繪製為圖表的方法、電腦程式產品及電腦可讀取媒體
ES3004932T3 (en) * 2020-04-02 2025-03-13 Glaxosmithkline Ip Dev Ltd Regimen for treating a neisseria gonorrhoeae infection with gepotidacin
CN117062598A (zh) * 2021-01-20 2023-11-14 恩塔西斯治疗有限公司 固定剂量抗生素组合物
WO2023206580A1 (en) * 2022-04-29 2023-11-02 Entasis Therapeutics Limited Durlobactam crystalline forms

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1046515C (zh) 1993-12-29 1999-11-17 辉瑞大药厂 二氮杂双环神经激肽拮抗剂
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
FR2914923B1 (fr) 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
PT2231667E (pt) * 2008-01-18 2013-12-13 Merck Sharp & Dohme Inibidores de beta-lactamase
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP2135959A1 (en) 2008-06-19 2009-12-23 Novexel Use of (1R,2S,5R) 1,6-Diazabicyclo [3,2,1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2936951B1 (fr) * 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2937034B1 (fr) 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
CN103687598B (zh) 2011-07-26 2016-03-16 沃克哈特有限公司 包括舒巴坦和β-内酰胺酶抑制剂的药物组合物
NZ617104A (en) * 2011-07-26 2015-05-29 Wockhardt Ltd Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
US8822450B2 (en) 2011-08-27 2014-09-02 Wockhardt Ltd. 1,6-diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
RU2570423C2 (ru) 2011-08-30 2015-12-10 Вокхардт Лимитед Производные 1,6-диазабицикло[3.2.1]октан-7-она и их применение при лечении бактериальных инфекций
CN103781787B (zh) 2011-09-13 2015-09-23 沃克哈特有限公司 含氮化合物及其用途
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
EP2814483A2 (en) * 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
US8933232B2 (en) 2012-03-30 2015-01-13 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
EP2831069B1 (en) 2012-03-30 2017-07-12 Merck Sharp & Dohme Corp. Isoxazole beta-lactamase inhibitors
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
PT2857401T (pt) 2012-05-30 2019-11-19 Meiji Seika Pharma Co Ltd Novo inibidor de β-lactamase e método para a produção do mesmo
EP2961751B1 (en) 2012-08-25 2018-03-21 Wockhardt Limited 1,6- diazabicyclo [3,2,1]octan- 7- one derivatives and their use in the treatment of bacterial infections
EP2934523A1 (en) * 2012-09-03 2015-10-28 Wockhardt Limited Antibacterial compositions
KR20150115761A (ko) * 2013-02-06 2015-10-14 아스트라제네카 아베 병원내 폐렴을 치료하기 위한 조합 요법
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
HUE044061T2 (hu) 2014-11-17 2019-09-30 Entasis Therapeutics Ltd Kombinációs terápia rezisztens bakteriális fertõzések kezelésére

Also Published As

Publication number Publication date
AU2015350128B2 (en) 2019-05-16
IL251979B (en) 2020-10-29
DK3221313T3 (en) 2019-04-08
CN107108624B (zh) 2020-01-07
RS58429B1 (sr) 2019-04-30
HK1244798B (en) 2020-02-21
CA2966632A1 (en) 2016-05-26
MX2017006383A (es) 2017-08-21
KR20170082635A (ko) 2017-07-14
MY196240A (en) 2023-03-24
ME03357B (me) 2019-10-20
CA2966632C (en) 2023-10-03
AU2015350128A1 (en) 2017-06-01
SI3221313T1 (sl) 2019-04-30
EP3221313A1 (en) 2017-09-27
PH12017500852A1 (en) 2017-11-06
LT3221313T (lt) 2019-03-25
PH12017500852B1 (en) 2023-03-08
US20180000800A1 (en) 2018-01-04
JP2017533945A (ja) 2017-11-16
ES2717776T3 (es) 2019-06-25
IL251979A0 (en) 2017-06-29
BR112017010132A2 (pt) 2018-01-02
US9968593B2 (en) 2018-05-15
CY1121384T1 (el) 2020-05-29
TW201625234A (zh) 2016-07-16
EA033829B1 (ru) 2019-11-29
WO2016081452A1 (en) 2016-05-26
KR102542392B1 (ko) 2023-06-09
HUE044061T2 (hu) 2019-09-30
EP3221313B1 (en) 2019-01-09
HRP20190580T1 (hr) 2019-05-17
SG11201703633TA (en) 2017-06-29
PL3221313T3 (pl) 2019-07-31
BR112017010132B1 (pt) 2023-02-14
JP6764862B2 (ja) 2020-10-07
US10376499B2 (en) 2019-08-13
NZ731601A (en) 2024-02-23
TWI690317B (zh) 2020-04-11
PT3221313T (pt) 2019-04-15
EA201791069A1 (ru) 2017-11-30
CN107108624A (zh) 2017-08-29
SMT201900187T1 (it) 2019-05-10
US20180289681A1 (en) 2018-10-11
ZA201703245B (en) 2019-08-28

Similar Documents

Publication Publication Date Title
TR201905233T4 (tr) Dirençli bakteriyel enfeksiyonların tedavisine yönelik kombinasyon tedavisi.
HK1244798A1 (en) Combination therapy for treatment of resistant bacterial infections
RU2560846C1 (ru) Фармацевтические композиции, содержащие сулбактам и ингибитор бета-лактамазы
WO2017203266A1 (en) Combination therapy for treatment of resistant bacterial infections
ES2929058T3 (es) Composiciones y procedimientos de uso de combinaciones de fármacos antibacterianos
RU2593363C2 (ru) Композиции, включающие антибактериальное средство и тазобактам
TWI725948B (zh) 有效對抗包括抗藥性微生物類之微生物群的組合治療
ES2428167T3 (es) Composición farmacéutica bactericida activa anti-MRSA conteniendo carbapenemos
US8946299B2 (en) Use of calixarenes associated with an antibiotic in the treatment of bacterial infections
CA3053441C (en) COMBINATION OF N-ACETYLCYSTEINE AND COLISTIN INTENDED FOR USE IN BACTERIAL INFECTIONS
CN106794250A (zh) 包含抗菌剂的药物组合物
US20200352912A1 (en) Antimicrobial compositions and methods of using the same
US20140066365A1 (en) Use of calixarenes associated with an antibiotic in the treatment of bacterial infections
US20150065416A1 (en) Novel drug combination
US10772900B2 (en) Drug target for treating veterinary infections and methods of using same